Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer

Yuko Matsubara, Keiichiro Nakamura, Hirofumi Matsuoka, Chikako Ogawa, Hisashi Masuyama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalMolecular and Clinical Oncology
Volume11
Issue number4
DOIs
Publication statusPublished - Oct 2019

Keywords

  • Low skeletal muscle mass
  • Ovarian cancer
  • Prognostic factor
  • Psoas area
  • Psoas major volume
  • Skeletal muscle area

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer'. Together they form a unique fingerprint.

  • Cite this